Becton, Dickinson and Company (BDX)
Summary
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Becton, Dickinson - Stable Undervaluation In 1Q26, Upside Is There
Becton, Dickinson and Company is undervalued, trading at 12–13x P/E despite forecasted 7%–8% annual growth and improving fundamentals. BDX's sector-wide pressures are driven by cautious hospital spending, higher rates, and capital rotation into AI, but its core operations remain robust. BDX maintains a BBB rating, conservative leverage, a 2.78% dividend with 44+ years of increases, and is executing $2B in buybacks while retiring $2.1B in debt.
Here's Why You Should Retain BDX Stock in Your Portfolio Now
Becton, Dickinson's MedTech focus, innovation push and strategic partnerships support growth optimism, though reimbursement uncertainty remains a key concern.
Becton, Dickinson and Company Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 24,200 | $4.04M | $3.78M | -$259,878.1 | -6.43% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 782.28 | $136,983.75 | $122,262.54 | -$14,721.21 | -10.75% |
| TMB Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 356.16 | $62,264.45 | $55,664.25 | -$6,600.2 | -10.6% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 2,670 | $497,499.84 | $417,641.4 | -$79,858.44 | -16.05% |
 Stonebridge Capital Management Stonebridge Capital Management Inc. | 6,232.8 | $327,553.48 | $974,934.58 | $647,381.1 | 197.64% |
Becton, Dickinson and Company (BDX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Becton, Dickinson and Company ever had a stock split?
Becton, Dickinson and Company Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Thomas E. Polen Jr. CEO | NYSE Exchange | 075887109 CUSIP |
| US Country | 70,000 Employees | 9 Jun 2026 Last Dividend | 10 Feb 2026 Last Split | - IPO Date |
Overview
Becton, Dickinson and Company, commonly known as BD, is a global leader in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. Catering to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public, BD operates worldwide. The company’s extensive product portfolio is strategically segmented into three core areas: BD Medical, BD Life Sciences, and BD Interventional. Founded in 1897, BD has established a robust presence in the healthcare sector, headquartered in Franklin Lakes, New Jersey.
Products and Services
- BD Medical:
This segment provides a comprehensive range of products, including peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, and vascular access technology. It also offers vascular care, preparation products, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detections, and a variety of syringes and needles. For drug delivery and safety, it covers IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, as well as automated medication dispensing and supply management systems, enhancing medication inventory optimization and tracking. Additionally, BD Medical produces prefillable drug delivery systems.
- BD Life Sciences:
In this area, BD presents an array of solutions for specimen and blood collection and an extensive selection of diagnostic tools, including automated culturing for blood and tuberculosis, molecular testing systems, products for microorganism identification, and drug susceptibility testing. The segment also specializes in liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media products. For cellular analysis, it offers fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, crucial for clinical oncology, immunological research, and transplantation diagnostics or monitoring.
- BD Interventional:
BD's interventional segment covers a wide range of surgical and medical products, including those for hernia and soft tissue repair, biosurgery, and surgical infection prevention. It also offers biological and bioresorbable grafts, peripheral intervention products, and equipment for urology and critical care. These products are designed to improve patient outcomes and support the efficiency of medical procedures.
